Issue Date: September 11, 2017
Merck buys cancer firm Rigontec
Bolstering its immuno-oncology pipeline, Merck & Co. will pay roughly $135 million to acquire the German biotech firm Rigontec. The deal adds RNA-based therapies targeting the retinoic acid-inducible gene I (RIG-I) pathway, a component of the innate immune system, and includes a RIG-I agonist in Phase I studies as a cancer treatment. Investors in Rigontec, which was spun off of the University of Bonn in 2014, could receive another $415 million if certain milestones are . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society